Methoxyamine hydrochloride - TRACON

Drug Profile

Methoxyamine hydrochloride - TRACON

Alternative Names: Methoxyamine - TRACON; TRC 102

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TRACON Pharmaceuticals
  • Developer Case Western Reserve University; National Cancer Institute (USA); TRACON Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Mesothelioma
  • Phase I/II Solid tumours
  • Phase I Haematological malignancies; Lymphoma; Non-small cell lung cancer

Most Recent Events

  • 13 Nov 2017 Adverse events data from a phase I trial in Haematological malignancies released by TRACON Pharmaceuticals
  • 15 Jun 2017 Methoxyamine hydrochloride is still in phase I trial for Lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) and in phase-I development in Solid-tumours (Combination therapy, Late-stage disease) in USA (IV, Infusion) (NCT01851369; NCT00892385)
  • 02 Jun 2017 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top